Rockville-based EntreMed shows loss in fourth quarter

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, reported a fourth-quarter net loss of $360, 4303, or 2 cents per diluted share, versus net income of 1 million, or 6 cents per diluted share, for the prior-year period.

Leave a Reply

Your email address will not be published. Required fields are marked *